Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 2;8(1):58–65. doi: 10.1002/sctm.18-0069

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

(A): Plan to confirm the implications of hedgehog (HH) signalling on autograft function. (B): Relative expression of GLI and 3BHSD upon SAG (Desert HH [DHH] agonist) treatment. (C): Comparison of testosterone levels in mice which received DHH antagonist (vismodegib) or DHH agonist (SAG). (D): Immunostaining showing cells expressing positive for 3BHSD, platelet‐derived growth factor receptor alpha, alpha smooth muscle actin, SOX9, and luteinizing hormone receptor in grafts from mice which received SAG‐treated Leydig stem cells. Significance of differences was calculated using t test; **, p < .01; *, p < .05, and ns (non‐significant) (p > .05). Abbreviations: BHSD, 3β‐Hydroxysteroid dehydrogenase; DAPI, 4′,6‐diamidino‐2‐phenylindole; LHR, luteinizing hormone receptor; LSC, Leydig stem cell; SAG, smoothened agonist; αSMA, alpha smooth muscle actin.